CA2107789A1 - Inhibition retrovirale par des acides nucleiques antisens complementaires de sequences d'encapsidation - Google Patents

Inhibition retrovirale par des acides nucleiques antisens complementaires de sequences d'encapsidation

Info

Publication number
CA2107789A1
CA2107789A1 CA002107789A CA2107789A CA2107789A1 CA 2107789 A1 CA2107789 A1 CA 2107789A1 CA 002107789 A CA002107789 A CA 002107789A CA 2107789 A CA2107789 A CA 2107789A CA 2107789 A1 CA2107789 A1 CA 2107789A1
Authority
CA
Canada
Prior art keywords
rna
antisense
dna
packaging
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002107789A
Other languages
English (en)
Inventor
Thomas E. Wagner
Lei Han
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ohio University
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2107789A1 publication Critical patent/CA2107789A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027New breeds of vertebrates
    • A01K67/0275Genetically modified vertebrates, e.g. transgenic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/05Animals comprising random inserted nucleic acids (transgenic)
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00Animals characterised by species
    • A01K2227/10Mammal
    • A01K2227/105Murine
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00Animals characterised by purpose
    • A01K2267/02Animal zootechnically ameliorated
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00Animals characterised by purpose
    • A01K2267/03Animal model, e.g. for test or diseases
    • A01K2267/0337Animal models for infectious diseases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
CA002107789A 1991-04-05 1992-04-03 Inhibition retrovirale par des acides nucleiques antisens complementaires de sequences d'encapsidation Abandoned CA2107789A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68087391A 1991-04-05 1991-04-05
US680,873 1991-04-05

Publications (1)

Publication Number Publication Date
CA2107789A1 true CA2107789A1 (fr) 1992-10-06

Family

ID=24732881

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002107789A Abandoned CA2107789A1 (fr) 1991-04-05 1992-04-03 Inhibition retrovirale par des acides nucleiques antisens complementaires de sequences d'encapsidation

Country Status (5)

Country Link
EP (1) EP0578776A4 (fr)
JP (1) JPH06506599A (fr)
AU (1) AU655279B2 (fr)
CA (1) CA2107789A1 (fr)
WO (1) WO1992017211A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4126484A1 (de) * 1991-08-10 1993-02-11 Bayer Ag Expressionsvektoren und deren verwendung zur darstellung hiv-resistenter menschlicher zellen fuer therapeutische anwendungen
DE4225094A1 (de) * 1992-04-28 1993-11-04 Frank Andreas Harald Meyer Medikament zur gentherapeutischen behandlung von menschen, tieren und pflanzen, insbesondere zur blockierung der virenvermehrung und der tumorgene sowie verfahren zur herstellung des medikaments
ES2312164T3 (es) 1992-09-25 2009-02-16 Aventis Pharma S.A. Vectores de adenovirus para la transferencia de genes extraños en celulas del sistema nervioso central, particularmente en el cerebro.
EP0598935A1 (fr) * 1992-11-24 1994-06-01 Bayer Ag Vecteurs d'expression et leur utilisation pour la production de cellules humaines résistantes à HIV pour utilisation thérapeutique
US5583035A (en) * 1992-12-07 1996-12-10 Bayer Aktiengesellschaft HIV antisense expression vectors
FR2702152B1 (fr) * 1993-03-03 1995-05-24 Inst Nat Sante Rech Med Virus recombinants et leur utilisation en thérapie génique.
US5712384A (en) * 1994-01-05 1998-01-27 Gene Shears Pty Ltd. Ribozymes targeting retroviral packaging sequence expression constructs and recombinant retroviruses containing such constructs
JP3691849B2 (ja) * 1994-01-05 2005-09-07 ジーン・シアーズ・ピーティーワイ・リミテッド レトロウイルスパッケージング配列を標的とするリボザイム、その発現構築物、および斯かる構築物を含む組換えレトロウイルス
KR100696410B1 (ko) * 1994-01-05 2008-11-07 진 쉬어즈 피티와이., 엘티디. 레트로바이러스 패키징 서열 발현 제작물을 표적으로 하는 리보자임 및 그러한 제작물을 가진 재조합 레트로바이러스
WO1995027783A1 (fr) * 1994-04-06 1995-10-19 Joshi Sukhwal Sadna Inhibition de la multiplication du vih-1 dans des cellules de mammiferes
US20020058636A1 (en) * 1994-09-21 2002-05-16 Geoffrey P. Symonds Ribozymes targeting the retroviral packaging sequence expression constructs and recombinant retroviruses containing such constructs
US7994144B2 (en) 2001-07-10 2011-08-09 Johnson & Johnson Research Pty, Limited Process for the preparation of a composition of genetically modified hematopoietic progenitor cells
NZ530624A (en) 2001-07-10 2009-02-28 Johnson & Johnson Res Pty Ltd Compositions comprising C34+ hematopoietic progenitor cells transformed with an anti-viral agent for treating HIV

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4757055A (en) * 1980-11-12 1988-07-12 The Johns Hopkins University Method for selectively controlling unwanted expression or function of foreign nucleic acids in animal or mammalian cells
US4740463A (en) * 1984-04-13 1988-04-26 Massachusetts Institute Of Technology Methods and artificial genes for antagonizing the function of an oncogene
WO1988010311A1 (fr) * 1987-06-26 1988-12-29 Syntro Corporation Cytomegalovirus humain recombinant contenant des genes etrangers et son utilisation
ATE208813T1 (de) * 1988-02-16 2001-11-15 Greatbatch Gen Aid Ltd Modifizierte zellen mit resistenz gegen retroviralinfektionen
EP0402402B1 (fr) * 1988-02-26 1995-12-27 Worcester Foundation For Biomedical Research, Inc. Inhibition du htlv-iii par des oligonucleotides exogenes

Also Published As

Publication number Publication date
JPH06506599A (ja) 1994-07-28
WO1992017211A1 (fr) 1992-10-15
AU1778092A (en) 1992-11-02
EP0578776A1 (fr) 1994-01-19
AU655279B2 (en) 1994-12-15
EP0578776A4 (fr) 1995-04-12

Similar Documents

Publication Publication Date Title
US7419829B2 (en) Vector system
Han et al. Inhibition of Moloney murine leukemia virus-induced leukemia in transgenic mice expressing antisense RNA complementary to the retroviral packaging sequences.
AU655279B2 (en) Retrovirus inhibition with antisense nucleic acids complementary to packaging sequences
WO1994020608A1 (fr) Vecteurs ameliores en therapie genique
WO1990013641A1 (fr) Cellules eucaryotes transformees de maniere stable comprenant un adn etranger susceptible d'etre transcrit sous la direction d'un promoteur pol iii
WO1995001447A1 (fr) Vecteur retroviral pour le transfert et l'expression de genes a visee therapeutique, dans des cellules eucaryotes
IL89701A (en) Recombinant retroviruses method for the production thereof and pharmaceutical compositions containing the same
JP2001501441A (ja) 複製能力ウイルスの産生を阻害するための方法および組成物
AU693317B2 (en) Retroviral vectors for expression in embryonic cells
US5989886A (en) Method for the inhibition and prevention of viral replication using fusions of a virus protein and a destructive enzyme
CA2158252A1 (fr) Systeme d'administration controle par des facteurs associes au vih et a la cellule
AU741764B2 (en) Retroviral vector particles produced in a baculovirus expression system
AU697095B2 (en) Expression of viral decoy proteins under the control of a locus control region and uses thereof
US6432709B1 (en) Encapsidation cell lines and expression vectors for transcomplementation of defective retroviral vectors
Kaptein et al. Expression pattern of CD2 locus control region containing retroviral vectors in hemopoietic cells in vitro and in vivo
JP2003501070A (ja) 阻害性RNA分子を決定するためのinvivoでの選択方法
Matesanz et al. In-vivo and in-vitro analysis of retroviral vectors carrying the N-ras oncogene
Lang et al. Development of transforming function during transduction of proto-ras into Harvey sarcoma virus.
Zhang et al. MOLECULAR TARGETING OF CANCER: RETROVIRAL VECTOR-MEDIATED ANTISENSE NUCLEIC ACID THERAPY
Majumdar The Soybean Retroelement, Sire-1, Encodes an Envelope-Like Protein-Sire-1 is an Endogenous, Proretrovirus-Like Genomic Element

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued
FZDE Discontinued

Effective date: 20010403